• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Is There an Ideal Patient for Comprehensive Genomic Profiling?


David Gandara, MD, explains how the scope of comprehensive genomic profiling has shifted from a select few patients to the majority.


David R. Gandara, MD: Our thinking about who should get next-generation sequencing done by a comprehensive genomic profiling platform has changed over the years. I’m referring to non–small cell lung cancer because this is the clearest example. Initially, we said, “Maybe this should be only in never-smokers, in adenocarcinoma, or this should just be in young patients in the United States who are Asian American because of a higher prevalence of EGFR-mutated disease. Our thinking has changed because if you find that abnormality, it’s like hitting a grand slam home run, using baseball terminology. Even if that patient has a prior smoking history, there’s still a significant chance you’ll find 1 of the oncogenes. It’s going to be much less—for example, for EGFR—but if you use next-generation sequencing, you test for all the abnormalities all at once.

A patient I recently saw who was Japanese American had a light smoking history. I suspected that he would have an EGFR mutation and instead he had an ALK translocation. I wasn’t looking for ALK—I was expecting EGFR—but this was tremendously important for this patient. Now it would be everyone with advanced-stage non–small cell lung cancer. In guidelines a case is being made for those with squamous cell lung cancer as well, particularly younger patients and those with a lighter smoking history. The reason is that although they’re less common, you can still find these abnormalities in squamous cell lung cancer. It’s like night and day in terms of the options for them.

One study where I wrote the editorial—the LUX-Lung 8—21% of patients with pure squamous cell lung cancer had a HER [human epidermal growth factor receptor] family mutation. EGFR is HER1, but there’s also HER1, HER2, HER3, HER4. The benefit in this trial for a pan-HER inhibitor like afatinib was markedly better in patients who had 1 of these abnormalities with very long survival in some of them. Today it’s everyone.

Transcript edited for clarity.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 8 - "Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization"
Video 7 - "Prescribing Prescription Drug Therapeutics: Factors for Providers and Payers to Consider"
Video 9 -"Overcoming Implementation Barriers for Digital Therapeutics Adoption"
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
© 2024 MJH Life Sciences

All rights reserved.